Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-10
2009-08-25
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S251000
Reexamination Certificate
active
07579356
ABSTRACT:
The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I):and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.
REFERENCES:
patent: 3635985 (1972-01-01), Santilli et al.
patent: WO 98/02434 (1998-01-01), None
patent: WO 03/040108 (2003-05-01), None
patent: WO 2004/046101 (2006-06-01), None
Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.
Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.
International Search Report, PCT/US06/13257, Aug. 25, 2006.
Olayioye, et al., “The ErbB signaling Network: Receptor Heterodimerization in Development and Cancer,” EMBO Journal, vol. 19, No. 13, pp. 3159-3167, 2000.
Yarden, et al., “Untangling The ErbB Signalling Network,” Molecular Cell Biology, vol. 2, Feb. 2001, pp. 127-137.
Klijn, et al., “The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients,” Endocrine Reviews, vol. 13, No. 1, pp. 3-17, 1992.
Salomon, et al., “The ErbB Family of Receptors and Their Ligands: Multiple Targets for Therapy,” 2001 Adis Int'l Ltd., vol. 2, Issue 3, pp. 4-11.
Ekstrand, et al., “Amplified and Rearranged Epidermal Growth Factor Receptor Genes in Human Glioblastomas Reveal Deletions of Sequences Encoding Portions of The N- and/or C- Terminal Tails,” Proc. Natl Acad. Sci. USA, vol. 89, pp. 4309-4313, May 1992 Medical Sciences.
Wilkstrand, et al., “Monoclonal Antibodies Against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas,” Cancer Research 55, Jul. 15, 1995, pp. 3140-3148.
Koprivica, et al., “EGFR Activation Mediates Inhibition of Axon Regeneration by Myelin and Chondroitin Sulfate Proteoglycans,” Science, Oct. 7, 2005, vol. 310, pp. 106-110.
Bertino, Rowinsky, “Targeting Signal Transduction,” Horizons, Oct. 30, 2001, vol. 2, 1532-3048.
Slamon, et al., “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene,” Articles, Jan. 9, 1987, pp. 177-182.
Slamon, et al., “Studies of The HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer,” Science, May 12, 1989, pp. 707-712.
Hetzel, et al., “HER-2
eu Expression: A Major Prognostic Factor in Endometrial Cancer,” Gynecologic Oncology 47, 1992, pp. 179-185.
Kirsch, et al., “Targeting HER2 in Brain Metastases from Breast Cancer,” Clinical Cancer Res., vol. 9, Nov. 15, 2003, pp. 5435-5436.
Grossi, et al., “Efficacy of Intracerebral Microinfusion of Trastuzumab in An Athymic Rat Model of Intracerebral Metastatic Breast Cancer,” Clinical Cancer Res., vol. 9, Nov. 15, 2003, pp. 5514-5520.
Wang, et al., “Epidermal Growth Factor Receptor is A Cellular Receptor for Human Cytomegalovirus,” Nature, vol. 424, Jul. 2003, pp. 456-461.
Yeatman, “A Renaissance for SRC,” Nature, vol. 4, Jun. 2004, pp. 470-480.
Goldenberg-Furmanov, et al., “Lyn Is A Target Gene for Prostate Cancer: Sequence-Based Inhibition Induces Regression of Human Tumor Xenografts,” Cancer Res. 64, Feb. 1, 2004, pp. 1058-1066.
Shah, et al., “Overriding Imatinib Resistance with A Novel ABL Kinase Inhibitor,” Science, vol. 305, Jul. 16, 2004, pp. 399-401.
Donato, et al., “BCR-ABL Independence and LYN Kinase Overexpression in Chronic Myelogenous Leukemia Cells Selected for Resistance to ST1571,” Blood, vol. 101, Jan. 15, 2003, No. 2, pp. 690-698.
Klotzer, et al., “Reaktionen Des 4,6-Dichlor-5-Formylpyrimidins,” Chem, 96, 1965, pp. 1567-1578.
Shiraishi, et al., “Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with A Quaternary Ammonium Moiety,” J.Med.Chem 2000, 43, pp. 2049-2063.
Clark, et al., “Heterocyclic Studies, Part 43, Thieno {2,3-d:4,5-d}Dipyrimidines,” J.Chem.Soc Perkin Trans 1984, pp. 2005-2008.
Ple, et al., “discovery of A New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for The Tyrosine Kinase Domain of c-Src,” Amer. Chem. Society, Jan. 14, 2004, 47, pp. 871-887.
Regan, et al., “Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate,” J.Med.Chem 2002, 45, pp. 2994-3008.
Battista Kathleen A.
Bignan Gilles C.
Connolly Peter J.
Hayden Stuart
Johnson Sigmond G.
Donnelly Laura
Janssen Pharmaceutica NV
Lesser Erich A
Wilson James O.
LandOfFree
Thia-tetraazaacenaphthylene kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thia-tetraazaacenaphthylene kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thia-tetraazaacenaphthylene kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4122394